 |
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
| Mission Statement |
|
|
|
|
|
| To be a leading supplier
and manufacturer of research chemicals to the global market,
providing a quality product on time, every time. |
| |
|
|
|
|
| Apollo Scientific
Ltd - a history |
|
|
|
|
|
Initially established
in 1993 as M&G Chemicals Limited, the company was renamed
as Apollo Scientific Limited in 1996 coinciding with its move
to a 170 sq.metre business centre in Stockport (near Manchester,
England).
By carrying out the sales and marketing in the UK and Europe
for a number of small scale international manufacturers Apollo
continued to expand. That year also saw the production of Apollo's
first technically detailed catalogue of fluorochemicals, listing
over 1000 items containing at least one or more fluorine atoms.
Worldwide demand for these products grew along with Apollo's
reputation as a supplier of competitively priced, high quality
fluorochemical products. Apollo had found its main niche.
Why fluorochemicals? It was clear to the staff at Apollo that
research interest into incorporating the fluorine atom into
organic molecules was growing strongly. The presence of the
fluorine atom can have a major influence on the physical and
biological properties and chemical reactivity of an organic
molecule, as witnessed by today's amazingly diverse range of
commercial products containing one or more C-F bonds (agrochemicals,
anaesthetics, fire-extinguishing agents, refrigerants, textile
chemicals, dyes, surfactants, inert oils and lubricants, elastomers,
plastics, liquid crystals, etc.). However, it was in the area
of healthcare in particular that the demand for fluorochemicals
has grown most strongly. Replacing hydrogen (for example) in
a molecule by the fluorine atom (which has a similar steric
size, but is much more electronegative) can have a dramatic
effect on biological activity. It is not surprising, therefore,
that many pharmaceutical products containing fluorine have been
approved for use as antibiotic, anticholesterol, anti-inflammatory,
antidepressant, antiviral and anticancer drugs.
Recognising this increase in demand for fluorochemicals from
medicinal chemists at pharmaceutical companies, Apollo concentrated
its efforts into offering from stock an ever-increasing range
of novel and difficult-to-source fluorine-containing compounds. |
Whalley Bridge premises |
By the time of Apollo's next move in
1998 to a 350 sq.metre site in Whaley Bridge, Derbyshire,
the company had grown to ten staff and a turnover approaching
1.5 million pounds. Its fluorochemicals catalogue that year
listed nearly 4000 compounds.
As the millennium came to a close Apollo began to establish
strong relationships with a number of key manufacturing companies
in China.
|
With the benefit of many
visits to production facilities in China, reliable, high quality
producers were located. With agreements then in place, when
an intermediate sourced from Apollo showed potential it was
then possible to offer it in quantities exceeding 100Kg. Indeed,
one of these relationships in particular enabled Apollo to become
a significant supplier of fluoroaromatic compounds into the
European liquid crystal market.
In 2001 Apollo decided it required its own small scale manufacturing
in the UK. Renting 600 sq.metres of modern laboratories and
offices on the Hickson and Welch site in Castleford and recruiting
highly skilled PhD chemists, Apollo quickly established a strong
reputation for manufacturing novel and interesting fluorochemical
and heterocyclic building blocks, aimed primarily at the pharmaceutical
research scientist. Working in up to 20 litre glassware, Apollo's
manufacturing strengths have included Grignard technology, Balz-Schiemann
and most classical and modern chemistry. |
|
|
|
|
|
Apollo Scientific Bredbury site |
|
|
|
|
|
Throughout this time Apollo
built on its success as a major supplier of fluorochemicals
by diversifying into other non-fluorinated compounds, driven
by identifying interesting functionality. Catalogues of organic
intermediates and biochemical reagents were produced. Apollo
continued to grow.
By the time of Apollo's next move in 2002 to a 1000 sq.metre
site (extended to 1350 sq.metres in 2007) in Bredbury, Stockport,
the company had grown to thirty staff and a turnover of nearly
4.5 million pounds. Its fluorochemicals catalogue that year
listed around 7000 compounds.
In 2003 Central Glass Co., Ltd of Japan (http://www.cg-germany.com/)
acquired a 33% holding in Apollo.
Central Glass has a history of over 70 years of commercial production
of a wide range of fluorochemical products, including Trifluoromethanesulphonic
acid and its anhydride, chiral and achiral fluoroorganic products,
speciality fluorinated gases and fluoropolymers. Through Central
Glass Apollo now had access to pilot plant and full scale production
facilities running to ISO and GMP standards.
The next four years saw Apollo grow rapidly as it expanded its
range of products, produced larger catalogues, increased its
levels of stocks significantly and recruited more technical
staff. Typically annual turnover during this period grew by
nearly 25%. By 2007 Apollo's turnover had exceeded 12 million
pounds. With over 50 staff (nearly half graduates in chemistry
to first degree or PhD level) Apollo now offered over 42,000
compounds (including over 12,000 fluorochemicals) through its
website and catalogues. The Bredbury site was certified to the
ISO9001 standard towards the end of the year. |
|
|
|
|
|
Apollo Scientific Denton
site |
In early 2008 a major expansion
of Apollo's facilities took place. This added about 2200 sq.metres
of warehouse and laboratory space (including a dedicated analytical
laboratory) and a further 150 sq.metres of office space at an
additional new site in Denton, Stockport. Even with the closure
of the laboratories at Castleford this still meant Apollo's
capacity for its own production had doubled. This has been essential
to meet the increasing outsourcing research chemical demands
of the pharmaceutical companies.
With its new, much larger warehousing Apollo can now look to
improve its service to its many thousands of customers throughout
the world by increasing its levels of inventory and further
improving its dispatch infrastructure.
At the end of March Central Glass increased its shareholding
in Apollo to 91%. This has enabled Apollo to position itself
more strategically in the research and development marketplace.
Central Glass had previously acquired the R&D company Synquest
Laboratories Inc. (Florida, USA) back in 2002. Synquest is a
manufacturer of a range of speciality fluorochemicals, including
gases and aliphatic compounds. It has particular strengths in
high pressure autoclave work and precise distillations. It distributes
a catalogue listing over 3500 fluorochemicals.
With Apollo now working much more closely with Synquest and
Central Glass, the three companies can help each other with
the production and marketing of their fluorochemical product
ranges throughout the world, from research quantities in the
laboratories to full scale pilot plant production. Announcements
as to the form these collaborations will take will be made at
forthcoming exhibitions.
Apollo can certainly look back with pride at its rapid growth
and successful history. |
| |
|
|
|
|
| Location |
|
|
|
|
|
| Link
to map showing locations of our two sites near Manchester. |
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
 |
|
|
|
|
|
|
PRODUCT SEARCH
|
|
|
